scholarly journals Review of Jwarahara Gutika Yogas Containing Vatsanabha in Sahasrayogam

2021 ◽  
pp. 70-78
Author(s):  
KV Reshma Phalgunan ◽  
Madavi Subhashchandra
Keyword(s):  
Clinical Trial ◽  
Well Being ◽  
Tablet Form ◽  
Medicinal Preparations ◽  
Current Scenario

Vatsanabha is Vishavarga dravya mentioned in many of the Ayurveda Samhitas, which is commonly used in Ayurvedic medicinal preparations. It has a property of Jwarahara, Amaghna, Swedajana which is very useful in Jwara cases. The drugs like Parada, Gandhaka, Hingula along with Vatsanabha shows fast action on Jwara. In Ayurveda there are many formulations mentioned with Jwarahara properties. In this article we are studying about 17 Jwarahara Gutika yogas containing Vatsanabha which are mentioned in Sahasrayogam. Purpose of this study is to analyse these Yoga in the aspect of their ingredients, Bhavana dravya, Anupana, Sevana vidhi, and their role in management of Jwara. When we analysing each and every ingredients on these Yogas there are certain similarities in ingredients, Bhavana dravya, Anupana of these medicines. Most of these ingredients have Deepana Pachana karma, Katu Thikta rasa, Ushna veerya, Katu vipaka etc which are beneficial for Samprapti vighatana of Jwara. As Sahasrayogam is a compilation of popular formulations which are commonly used by ancient physicians of Kerala, it is assumed that all of this Yoga were once in practice. These formulations are to be kept in tablet form which is very convenient for their administration, palatability etc. But very few of them are available in market. In this current scenario of Covid pandemic Ayurveda field should rethink about these potent medicines of Jwara for the well being of our community, and further study and clinical trial also needed to know their action on Jwara.

scholarly journals Randomized clinical trial of a community navigation intervention to improve well-being in persons living with HIV and other co-morbidities

AIDS Care ◽  
2018 ◽  
Vol 31 (5) ◽  
pp. 529-535 ◽  
Author(s):  
Allison Webel ◽  
Maryjo Prince-Paul ◽  
Stephen Ganocy ◽  
Evelina DiFranco ◽  
Charles Wellman ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Well Being ◽  
Persons Living With Hiv ◽  
Community Navigation ◽  
Living With Hiv

The brain metastasis journey: Experience from patient, caregiver, and physician surveys on diagnosis and treatment of brain metastases.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e14004-e14004
Author(s):  
Albert Eusik Kim ◽  
GI-Ming WANG ◽  
Kristin A Waite ◽  
Scott Elder ◽  
Avery Fine ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Brain Metastases ◽  
Checkpoint Inhibitors ◽  
Treatment Options ◽  
Whole Brain Radiotherapy ◽  
Well Being ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Brain Radiotherapy

e14004 Background: Brain metastases (BM) is one of the most feared complications of cancer due to substantial neurologic sequalae, neuro-cognitive morbidity and grim prognosis. In the past decade, targeted therapies and checkpoint inhibitors have resulted in meaningfully improved overall survival for a minority of these patients. Accordingly, there is a growing need to identify issues surrounding patient survivorship and to standardize physician practice patterns for these patients. To date, there has not been a well-conducted formal study to specifically explore these questions of survivorship and practice standardization for BM patients. Methods: Here, we present results from a cross-sectional survey in which we analyzed responses from 237 BM patients, 209 caregivers, and 239 physicians. Surveys contained questions about BM symptoms, discussion of BM diagnosis by the clinician, psychosocial concerns, available treatment options for BM, BM patient advocacy resources, and BM-specific clinical trials. Results: Our survey revealed compelling findings about current care of BM patients. There were discrepancies in the perceived discussion of the implications of the diagnosis of BM, from the patient/caregiver and physician perspective. Important topics, such as prognosis and worrisome symptoms, were felt to have been discussed more frequently by physicians than by patients or caregivers. In our physician survey, private practice physicians, compared to academic physicians, were significantly more likely to recommend whole brain radiotherapy (61.1 vs 39.7%; p = 0.009). Participation in a clinical trial was one of the least recommended treatment options. Many physicians (59.1% private; 71.9% academic) stated that BM patients in their care are denied participation in a clinical trial, specifically due to the presence of BM. The consensus among physicians, patients and caregivers was that the highest yield area for federal assistance is increased treatment and research funding for BM. Conclusions: Our hope is that these findings will serve as a basis for future quality improvement measures to enhance patient-physician communication and patient well-being, continuing medical education activities detailing latest advances in BM for oncologists, and lobbying efforts to the federal government in prioritizing BM research, clinical trials, and patient survivorship.

scholarly journals Continued Access to Investigational Medicinal Products for Clinical Trial Participants—An Industry Approach

2018 ◽  
Vol 28 (1) ◽  
pp. 124-133 ◽  
Author(s):  
ARIELLA KELMAN ◽  
ANNA KANG ◽  
BRIAN CRAWFORD
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Pharmaceutical Research ◽  
Development Program ◽  
Well Being ◽  
Third Party ◽  
Clinical Development Program ◽  
Clinical Trial Evidence ◽  
Access To Medical Care ◽  
Trial Participants

Abstract:In the conduct of clinical trials for pharmaceutical research, access to investigational medicines following clinical trials is often necessary for the continued health and well-being of the trial participants; it is an ethical obligation under some circumstances, as outlined in the Declaration of Helsinki 2013 Article 34. This obligation becomes particularly important in lower-income countries, where access to medical care may be limited. Although there is agreement among global research and bioethics communities that continued access should be provided with prospectively defined parameters and procedures, the process is complex, as many responsible parties and complicated logistics are involved. Roche Pharmaceuticals developed and publicly posted the company’s policy regarding continued access to investigational medicines in 2013. This article provides insights on the policy, including the parameters that determine when continued access is and is not considered to be appropriate, along with an example from an active clinical development program. It also describes how multiple stakeholders, including those in academia, industry, government, and patient advocacy, have worked together to assess approaches to continued access. Continued access plans should be transparent and agreed to by research participants, investigators, and governments prior to the study and reassessed based on clinical trial evidence of safety and efficacy and availability of adequate treatments, along with relevant international laws and customs. Conducting responsible continued access programs requires close partnerships with investigators, health authorities, and third-party research partners.

scholarly journals Neuroplasticity induced by general anaesthesia: study protocol for a randomised cross-over clinical trial exploring the effects of sevoflurane and propofol on the brain – A 3-T magnetic resonance imaging study of healthy volunteers

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Signe Sloth Madsen ◽  
Kirsten Møller ◽  
Karsten Skovgaard Olsen ◽  
Mark Bitsch Vestergaard ◽  
Ulrich Lindberg ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Clinical Trial ◽  
Cognitive Function ◽  
Magnetic Resonance ◽  
Healthy Volunteers ◽  
General Anaesthesia ◽  
Well Being ◽  
Resonance Imaging ◽  
Link Type ◽  
The Brain

Abstract Background Although used extensively worldwide, the effects of general anaesthesia on the human brain remain largely elusive. Moreover, general anaesthesia may contribute to serious conditions or adverse events such as postoperative cognitive dysfunction and delirium. To understand the basic mechanisms of general anaesthesia, this project aims to study and compare possible de novo neuroplastic changes induced by two commonly used types of general anaesthesia, i.e. inhalation anaesthesia by sevoflurane and intravenously administered anaesthesia by propofol. In addition, we wish to to explore possible associations between neuroplastic changes, neuropsychological adverse effects and subjective changes in fatigue and well-being. Methods This is a randomised, participant- and assessor-blinded, cross-over clinical trial. Thirty healthy volunteers (male:female ratio 1:1) will be randomised to general anaesthesia by either sevoflurane or propofol. Multimodal magnetic resonance imaging (MRI) of the brain will be performed before and after general anaesthesia and repeated after 1 and 8 days. Each magnetic resonance imaging session will be accompanied by cognitive testing and questionnaires on fatigue and well-being. After a wash-out period of 4 weeks, the volunteers will receive the other type of anaesthetic (sevoflurane or propofol), followed by the same series of tests. Primary outcomes: changes in T1-weighted 3D anatomy and diffusion tensor imaging. Secondary outcomes: changes in resting-state functional magnetic resonance imaging, fatigue, well-being, cognitive function, correlations between magnetic resonance imaging findings and the clinical outcomes (questionnaires and cognitive function). Exploratory outcomes: changes in cerebral perfusion and oxygen metabolism, lactate, and response to visual stimuli. Discussion To the best of our knowledge, this is the most extensive and advanced series of studies with head-to-head comparison of two widely used methods for general anaesthesia. Recruitment was initiated in September 2019. Trial registration Approved by the Research Ethics Committee in the Capital Region of Denmark, ref. H-18028925 (6 September 2018). EudraCT and Danish Medicines Agency: 2018-001252-35 (23 March 2018). www.clinicaltrials.gov, ID: NCT04125121. Retrospectively registered on 10 October 2019.

scholarly journals Enhancing Multiple Domains of Well-Being by Decreasing Multiple Health Risk Behaviors: A Randomized Clinical Trial

2012 ◽  
Vol 15 (5) ◽  
pp. 276-286 ◽  
Author(s):  
James O. Prochaska ◽  
Kerry E. Evers ◽  
Patricia H. Castle ◽  
Janet L. Johnson ◽  
Janice M. Prochaska ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Health Risk ◽  
Randomized Clinical Trial ◽  
Risk Behaviors ◽  
Well Being ◽  
Health Risk Behaviors ◽  
Multiple Domains ◽  
Multiple Health

scholarly journals A Randomized Placebo-Controlled Clinical Trial to Evaluate the Medium-Term Effects of Oat Fibers on Human Health: The Beta-Glucan Effects on Lipid Profile, Glycemia and inTestinal Health (BELT) Study

Nutrients ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 686 ◽  
Author(s):  
Arrigo F.G. Cicero ◽  
Federica Fogacci ◽  
Maddalena Veronesi ◽  
Enrico Strocchi ◽  
Elisa Grandi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Lipid Profile ◽  
Plasma Lipids ◽  
Plasma Concentrations ◽  
Well Being ◽  
Controlled Clinical Trial ◽  
Intestinal Health ◽  
Beta Glucan ◽  
Double Blind ◽  
Beta Glucans

The Beta-glucan Effects on Lipid profile, glycemia and inTestinal health (BELT) Study investigated the effect of 3 g/day oat beta-glucans on plasma lipids, fasting glucose and self-perceived intestinal well-being. The Study was an 8-week, double-blind, placebo-controlled, cross-over randomized clinical trial, enrolling a sample of 83 Italian free-living subjects, adherent to Mediterranean diet, with a moderate hypercholesterolemia and a low cardiovascular risk profile. Beta-glucans reduced mean LDL-Cholesterol (LDL-C) levels from baseline by 12.2% (95%CI: −15.4 to −3.8) after 4 weeks of supplementation and by 15.1% (95%CI: −17.8 to −5.9) after 8 weeks of supplementation (p < 0.01 for both comparison and versus placebo). Between baseline and 4 weeks Total Cholesterol (TC) levels showed an average reduction of 6.5% (95%CI: −10.9 to −1.9) in the beta-glucan sequence; while non-HDL-C plasma concentrations decreased by 11.8% (95%CI: −14.6 to −4.5). Moreover, after 8 weeks of beta-glucan supplementation TC was reduced by 8.9% (95%CI: −12.6 to −2.3) and non-HDL-C levels by 12.1% (95%CI: −15.6 to −5.3). Decreses in TC and non HDL-C were significant also versus placebo (respectively p < 0.05 and p < 0.01 to both follow-up visits). Fasting plasma glucose and self-perceived intestinal well-being were not affected by both beta-glucan and placebo supplementation.

Index of Psychological Well-being at Work—Validation of Tool in the Indian Organizational Context

2018 ◽  
Vol 22 (2) ◽  
pp. 174-184 ◽  
Author(s):  
Gargi Sandilya ◽  
Ghazi Shahnawaz
Keyword(s):  
Organizational Context ◽  
Well Being ◽  
Psychological Well Being ◽  
Five Dimensions ◽  
Work Related ◽  
Order Construct ◽  
Convergent And Divergent Validity ◽  
Current Scenario ◽  
Automotive Parts ◽  
Context Specific

Well-being has been a much valued emotion culling the interest of philosophers and researchers alike. Well-being at work is an even more significant construct in the current scenario where each individual invests more than half of their waking hours in work or work-related activities. While some researchers have worked on indigenous tools to measure generic well-being in the Indian cultural arena, there are no indigenous context-specific tools to measure well-being at work. Internationally, only three models for well-being at work were found. This article attempts to fill the gap in current literature by validating the Index of Psychological Well-being at Work (IPWBW) designed by Dagenais-Desmarais and Savoie (2011, What is psychological well-being, really? A grassroots approach from the organizational sciences. Journal of Happiness Studies, 13(4), 659–684) for the employees working in India. The sample in this study consists of employees from automobile and automotive parts manufacturers. Construct validity of IPWBW was established using confirmatory factor analysis, establishing convergent and divergent validity as well as getting Cronbach’s alpha for the scale. The final scale has 17 items across five dimensions. Psychological well-being at work was also established as a higher order construct.

Sign in / Sign up

Export Citation Format

Share Document